• Profile
Close

Effects of celecoxib and low-dose aspirin on outcomes in adjuvant aromatase inhibitor–treated patients: CCTG MA.27

Journal of the National Cancer Institute Jul 13, 2018

Strasser-Weippl K, et al. - Researchers investigated whether celecoxib and low-dose aspirin decreases the risk of breast cancer recurrence in postmenopausal hormone receptor–positive breast cancer patients who were randomly assigned (2 × 2) to adjuvant exemestane or anastrozole, and celecoxib or placebo in the Canadian Cancer Trials Group MA.27. They assessed the impacts of celecoxib and low-dose aspirin on event-free survival (EFS), distant disease–free survival (DDFS), and overall survival. All statistical tests were two-sided. In multivariable analysis, DDFS and EFS remained unaltered following random assignment to short-term (≤ 18 months) celecoxib as well as use of low-dose aspirin. The observed increase in “all-cause” mortality induced by low-dose aspirin was presumably attributed to higher preexisting cardiovascular risks.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay